Diabetes Drugs
- All
- News
- Videos
-
Obesity: Why New Medications Are Not Miracle Cures
Recently, new drugs - analogs of the gut hormone glucagon-like peptide-1 (GLP-1) have been added to the therapeutic arsenal, raising new hopes. However, they alone will not be enough to conquer obesity.
-
Some Diabetes Patients Achieve Remission With GLP-1 Drugs: Italian Study
An Italian study shows that using GLP-1 receptor agonists can lead to remission in up to 18% of cases, especially when used early and in patients with fewer complications.
-
New Study Finds Diabetes, Weight Loss Drugs May Lower Rheumatoid Arthritis Flares
A study presented at ACR Convergence 2025 suggests that GLP 1 receptor agonists reduce flares and systemic inflammation in Rheumatoid Arthritis (RA) patients.
-
Ozempic Is Here In India But It's Not A Magic Weight Loss Pill, Says Nutritionist
Ozempic arrives in India, but nutritionist Nmami Agarwal encourages reasonable expectations amid the hype.
-
"Unusual" Side Effect of Ozempic-Like Drugs Challenges Doctors: Research
GLP-1 medications, Ozempic and Wegovy, may disrupt cancer imaging and its diagnosis, new research has revealed.
-
Ozempic Coming Soon To India: 14 Facts About The Diabetes, Weight Loss Drug
Semaglutide (Ozempic), a once-weekly injectable already approved globally, has now been cleared for use in India for type 2 diabetes.
-
Ozempic Cleared For Use In India: Pros, Cons And Expected Price
Ozempic is the trade name for semaglutide, a once-weekly injectable medicine that belongs to the class called GLP-1 receptor agonists. A higher-dose semaglutide better known as Wegovy is licensed for chronic weight management.
-
Rising Diabetes In US Kids: Can Mounjaro Be The Answer? New Study Says Yes
A new study reveals Mounjaro may help children as young as 10 manage Type 2 diabetes, significantly reducing blood sugar and weight, with Eli Lilly pushing to expand its use beyond adults.
-
Lilly's Obesity Pill Will Have Far-Reaching Effect, Doctors Say
Oral versions of popular weight-loss shots are some of the next big things in the obesity market, which Bloomberg Intelligence estimates will reach $100 billion in annual sales by 2030.
-
AI Revolutionising Fight Against Cancer And Diabetes
AI in drug discovery Artificial intelligence is rapidly transforming the way new drugs and therapeutic targets are discovered in cancer immunology.
-
Higher Doses Of Semaglutide Safe, Can Aid In Better Weight Loss For Obese Adults: Study
A study published in The Lancet Diabetes & Endocrinology journal, suggest that a higher dose of semaglutide offers a promising new option for people who have not achieved sufficient weight loss with existing treatments.
-
WHO Adds Key Diabetes, Weight-Loss Drugs To Essential Medicines List
The World Health Organization has added key GLP-1 drugs, semaglutide and tirzepatide, to its Essential Medicines List for type 2 diabetes with obesity or comorbidities.
-
WHO Backs Weight-Loss Drugs To Treat Diabetes, Obesity, Urges Cheap Generics
The World Health Organization recommended a range of blockbuster weight-loss drugs to treat diabetes and obesity globally for the first time on Friday, calling for cheap generic versions to be made available for people in developing countries.
-
This New Weight Loss Drug Beats All Current Treatments In New Clinical Trial
A new drug, ecnoglutide, may outperform current weight-loss treatments like Ozempic by targeting a specific metabolic pathway, showing strong results in recent trials.
-
Boy, Diagnosed With Typhoid, Prescribed Drugs To Treat Diabetes, Heart Issue In Maharashtra
A ten-year-old boy, who was diagnosed with typhoid and pneumonia, was prescribed medicines used in the treatment of type 2 diabetes and heart-related chest pain (angina) in Maharashtra's Kalyan, close to Mumbai.
-
Obesity: Why New Medications Are Not Miracle Cures
Recently, new drugs - analogs of the gut hormone glucagon-like peptide-1 (GLP-1) have been added to the therapeutic arsenal, raising new hopes. However, they alone will not be enough to conquer obesity.
-
Some Diabetes Patients Achieve Remission With GLP-1 Drugs: Italian Study
An Italian study shows that using GLP-1 receptor agonists can lead to remission in up to 18% of cases, especially when used early and in patients with fewer complications.
-
New Study Finds Diabetes, Weight Loss Drugs May Lower Rheumatoid Arthritis Flares
A study presented at ACR Convergence 2025 suggests that GLP 1 receptor agonists reduce flares and systemic inflammation in Rheumatoid Arthritis (RA) patients.
-
Ozempic Is Here In India But It's Not A Magic Weight Loss Pill, Says Nutritionist
Ozempic arrives in India, but nutritionist Nmami Agarwal encourages reasonable expectations amid the hype.
-
"Unusual" Side Effect of Ozempic-Like Drugs Challenges Doctors: Research
GLP-1 medications, Ozempic and Wegovy, may disrupt cancer imaging and its diagnosis, new research has revealed.
-
Ozempic Coming Soon To India: 14 Facts About The Diabetes, Weight Loss Drug
Semaglutide (Ozempic), a once-weekly injectable already approved globally, has now been cleared for use in India for type 2 diabetes.
-
Ozempic Cleared For Use In India: Pros, Cons And Expected Price
Ozempic is the trade name for semaglutide, a once-weekly injectable medicine that belongs to the class called GLP-1 receptor agonists. A higher-dose semaglutide better known as Wegovy is licensed for chronic weight management.
-
Rising Diabetes In US Kids: Can Mounjaro Be The Answer? New Study Says Yes
A new study reveals Mounjaro may help children as young as 10 manage Type 2 diabetes, significantly reducing blood sugar and weight, with Eli Lilly pushing to expand its use beyond adults.
-
Lilly's Obesity Pill Will Have Far-Reaching Effect, Doctors Say
Oral versions of popular weight-loss shots are some of the next big things in the obesity market, which Bloomberg Intelligence estimates will reach $100 billion in annual sales by 2030.
-
AI Revolutionising Fight Against Cancer And Diabetes
AI in drug discovery Artificial intelligence is rapidly transforming the way new drugs and therapeutic targets are discovered in cancer immunology.
-
Higher Doses Of Semaglutide Safe, Can Aid In Better Weight Loss For Obese Adults: Study
A study published in The Lancet Diabetes & Endocrinology journal, suggest that a higher dose of semaglutide offers a promising new option for people who have not achieved sufficient weight loss with existing treatments.
-
WHO Adds Key Diabetes, Weight-Loss Drugs To Essential Medicines List
The World Health Organization has added key GLP-1 drugs, semaglutide and tirzepatide, to its Essential Medicines List for type 2 diabetes with obesity or comorbidities.
-
WHO Backs Weight-Loss Drugs To Treat Diabetes, Obesity, Urges Cheap Generics
The World Health Organization recommended a range of blockbuster weight-loss drugs to treat diabetes and obesity globally for the first time on Friday, calling for cheap generic versions to be made available for people in developing countries.
-
This New Weight Loss Drug Beats All Current Treatments In New Clinical Trial
A new drug, ecnoglutide, may outperform current weight-loss treatments like Ozempic by targeting a specific metabolic pathway, showing strong results in recent trials.
-
Boy, Diagnosed With Typhoid, Prescribed Drugs To Treat Diabetes, Heart Issue In Maharashtra
A ten-year-old boy, who was diagnosed with typhoid and pneumonia, was prescribed medicines used in the treatment of type 2 diabetes and heart-related chest pain (angina) in Maharashtra's Kalyan, close to Mumbai.
